StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
6-factor scoring with sector-relative rank. Updated daily.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-12 | $1.49 | $1.63 | +9.40% | 0.1M |
| 05-13 | $1.69 | $1.56 | -7.69% | 0.1M |
| 05-14 | $1.55 | $1.72 | +10.97% | 0.2M |
| 05-15 | $1.65 | $1.64 | -0.61% | 0.2M |
| 05-18 | $1.62 | $1.59 | -1.85% | 0.0M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
| Metric | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 | Q1 2025 2025-03-31 |
|---|---|---|---|---|
Revenue | $130.00K | $130.00K | $130.00K | $0.00 |
Operating Income | $-24.02M | $-17.82M | $-11.42M | $-5.86M |
Net Income | $-19.18M | $-15.85M | $-11.26M | $-4.81M |
EPS (Diluted) | $-1.91 | $-1.60 | $-1.15 | $-0.49 |
Total Assets | $6.95M | $12.41M | $8.94M | $6.73M |
Total Liabilities | $6.99M | $10.82M | $7.29M | $5.17M |
Cash & Equivalents | $3.06M | $8.62M | $6.04M | $4.27M |
Free Cash Flow OCF − CapEx | $-18.01M | $-11.98M | $-8.12M | $-4.32M |
Shares Outstanding | 10.77M | 10.54M | 10.14M | 9.93M |
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The company has one reportable segment relating to the research and development of its POZ platform. The segment derives its revenues from Grant revenue. Its main product candidate, SER-252 for advanced Parkinson's disease, is anticipated to enter clinical trials.